ATAI Life Sciences NV

As of October 10, 2025, ATAI Life Sciences NV shows a mildly bullish trend with strong performance, having returned 283.46% year-to-date compared to the S&P 500's 11.41%, despite some bearish signals in RSI and Dow Theory.

As of October 10, 2025, ATAI Life Sciences NV shows a mildly bullish trend with strong performance, having returned 283.46% year-to-date, despite some bearish signals from the RSI and Dow Theory.

As of September 11, 2025, ATAI Life Sciences NV shows a bullish trend supported by strong daily moving averages and weekly KST, despite some bearish momentum in weekly and monthly RSI readings, and has significantly outperformed the S&P 500 with year-to-date and one-year returns of 254.89% and 280.65%, respectively.

As of May 14, 2025, ATAI Life Sciences NV is considered risky due to overvaluation indicated by a price-to-book ratio of 3.18, an EV to EBITDA of -4.41, and a negative ROCE of -130.41%, despite a strong year-to-date stock performance of 254.89%.

As of May 14, 2025, ATAI Life Sciences NV is considered risky and overvalued due to significant negative financial metrics, including a P/E ratio that is not applicable, a Price to Book Value of 3.18, an EV to Sales ratio of 215.20, and poor returns on capital and equity, despite a year-to-date return of 51.88%.

As of May 28, 2025, the technical trend is bullish with strong daily moving averages and a bullish weekly MACD, though caution is advised due to a bearish monthly KST and mixed signals from longer-term indicators.

ATAI Life Sciences NV is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $2 million and a net loss of $26 million as of March 2025, with a market cap of $445.67 million. Key metrics include a P/E ratio of NA, a dividend yield of 0.00%, and a return on equity of -63.76%.

As of Jun 18, ATAI Life Sciences NV has a market capitalization of 445.67 million, with net sales of 1.87 million and a net profit of -137.53 million over the latest four quarters. The company reported shareholder's funds of 116.30 million and total assets of 159.39 million as of Dec 24.